In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin

Anastasiou, Diane; Thorne, Grace M.; Luperchio, Steven A.; Alder, Jeff

doi:10.1016/j.ijantimicag.2006.07.017

Cited by 34 publications

(22 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, daptomycin has been shown to have in vitro activity against enterococci resistant to other antibiotics [21]. Importantly, daptomycin has demonstrated in vitro activity against organisms with reduced susceptibility to vancomycin [17], linezolid and quinupristin/dalfopristin [22]. Finally, in an in vitro pharmacodynamic model with simulated endocarditis vegetations, daptomycin demonstrated greater bacterial reduction than vancomycin against enterococcal isolates [23].…”

Section: Discussionmentioning

confidence: 99%

Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin® Outcomes Registry and Experience (CORE)

Mohr¹,

Friedrich²,

Yankelev³

et al. 2009

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin® Outcomes Registry and Experience (CORE)

Mohr¹,

Friedrich²,

Yankelev³

et al. 2009

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…Daptomycin also displays in vitro activity against almost all Enterococcus spp., including those resistant to other antibiotics, such as vancomycin, linezolid (LZD), and quinupristindalfopristin (3,22,38). Daptomycin exhibits a lower potency against enterococci than that against staphylococci, demonstrating higher Clinical Laboratory and Standards Institute (CLSI) breakpoints (Յ4 g/ml versus Յ1 g/ml), MIC 50 values (1 to 2 g/ml versus 0.25 g/ml), and MIC 90 values (1 to 2 g/ml versus 0.5 g/ml) (11,38).…”

mentioning

confidence: 99%

Evaluation of Standard- and High-Dose Daptomycin versus Linezolid against Vancomycin-Resistant Enterococcus Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations

Hall

Steed

Arias

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Daptomycin MICs for enterococci are typically 1-to 2-fold higher than those for Staphylococcus aureus, and there is an imminent need to establish the optimal dose for appropriate treatment of enterococcal infections. We investigated the bactericidal activity of daptomycin at various dose exposures compared to that of linezolid against vancomycin-resistant enterococcus (VRE) in an in vitro pharmacokinetic/pharmacodynamic model utilizing simulated endocardial vegetations over 96 h. Daptomycin at doses of 6, 8, 10, and 12 mg/kg of body weight/day and linezolid at a dose of 600 mg every 12 h were evaluated against two clinical vancomycin-resistant Enterococcus faecium strains (EFm11499 and 09-184D1051), one of which was linezolid resistant (09-184D1051), and one clinical vancomycin-resistant Enterococcus faecalis strain (EFs11496). Daptomycin MICs were 4, 2, and 0.5 g/ml for EFm11499, 09-184D1051, and EFs11496, respectively. Bactericidal activity, defined as a >3 log 10 CFU/g reduction from the initial colony count, was demonstrated against all three isolates with all doses of daptomycin; however, bactericidal activity was not sustained with the daptomycin 6-and 8-mg/kg/day regimens. Linezolid was bacteriostatic against EFm11499 and displayed no appreciable activity against 09-184D1051 or EFs11496. Concentration-dependent killing was displayed with more sustained reduction in colony count (3.58 to 6.46 and 5.89 to 6.56 log 10 CFU/g) at 96 h for the simulated regimen of daptomycin at doses of 10 and 12 mg/kg/day, respectively (P < 0.012). No E. faecium mutants with reduced susceptibility were recovered at any dosage regimen; however, the E. faecalis strain developed reduced daptomycin susceptibility with daptomycin at 6, 8, and 10 but not at 12 mg/kg/day. Daptomycin displayed a dose-dependent response against three VRE isolates, with high-dose daptomycin producing sustained bactericidal activity. Further research is warranted. D aptomycin (DAP) is a lipopeptide antibiotic with concentration-dependent activity against Gram-positive bacteria that is currently approved for the treatment of staphylococcus bacteremia and right-sided endocarditis at a dose of 6 mg/kg of body weight/day (7). Daptomycin also displays in vitro activity against almost all Enterococcus spp., including those resistant to other antibiotics, such as vancomycin, linezolid (LZD), and quinupristindalfopristin (3, 22, 38). Daptomycin exhibits a lower potency against enterococci than that against staphylococci, demonstrating higher Clinical Laboratory and Standards Institute (CLSI) breakpoints (Յ4 g/ml versus Յ1 g/ml), MIC 50 values (1 to 2 g/ml versus 0.25 g/ml), and MIC 90 values (1 to 2 g/ml versus 0.5 g/ml) (11, 38). Based on in vivo neutropenic mice infection models, maximum concentration (C max )/MIC and area under the concentration-time curve (AUC)/MIC ratios are the best predictors for efficacy of daptomycin against infections caused by both Staphylococcus spp. and Enterococcus spp. (39) Additionally, in vitro pharmacokinetic/pharmacodynamic (P...

show abstract

“…More important, daptomycin can be used against resistant strains including VRE and MRSA with a high safety profile [46,47]. In vitro evidence suggests that daptomycin 305 EMERGING RESISTANCE is effective against gram-positive isolates less susceptible to linezolid and quinupristin/dalfopristin [48].…”

Section: Lipopeptidementioning

confidence: 99%

An Infectious Disease Update on Antibiotics: Emerging Resistance

Steinberg

Kim

Abbruzzese

2007

Clinics in Podiatric Medicine and Surgery

View full text Add to dashboard Cite

In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin

Cited by 34 publications

References 13 publications

Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin® Outcomes Registry and Experience (CORE)

Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin® Outcomes Registry and Experience (CORE)

Evaluation of Standard- and High-Dose Daptomycin versus Linezolid against Vancomycin-Resistant Enterococcus Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations

An Infectious Disease Update on Antibiotics: Emerging Resistance

Contact Info

Product

Resources

About